| Ytd | -17.93% | |
| 1y | -28.10% |
| Open | 4.86 | Prev Close | 4.86 | Low | 4.86 | High | 4.95 | Mkt Cap | 117.42M |
| Vol | 1.53K | Avg Vol | 399.38K | EPS | -0.74 | P/E | -6.57 | Forward P/E | -5.96 |
| Beta | 2.02 | Short Ratio | 3.12 | Inst. Own | 57.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 4.38 | 200-d Avg | 5.52 | 1yr Est | 6.25 |
XGN News
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of
Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers D
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Ex
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as ex
Exagen Inc. (XGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estim
CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider o
Exagen Inc. (NASDAQ: XGN - Get Free Report) has been given an average recommendation of "Moderate Bu
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus
Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force e
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the
CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider o
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy"
CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of
Exagen Inc. ( XGN ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Ryan Dou
Monday saw 825 companies set new 52-week lows.
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earn